 Tin Su
Concepts (305)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drosophila melanogaster | 28 | 2024 | 191 | 7.660 |
Why?
| | Drosophila Proteins | 22 | 2022 | 164 | 5.620 |
Why?
| | Drosophila | 16 | 2019 | 133 | 4.560 |
Why?
| | Radiation, Ionizing | 12 | 2020 | 72 | 2.480 |
Why?
| | Cell Cycle | 17 | 2020 | 542 | 2.300 |
Why?
| | Regeneration | 6 | 2022 | 160 | 2.200 |
Why?
| | Apoptosis | 15 | 2022 | 2362 | 2.140 |
Why?
| | DNA Damage | 15 | 2020 | 351 | 1.650 |
Why?
| | Caspases | 4 | 2020 | 245 | 1.570 |
Why?
| | Imaginal Discs | 5 | 2019 | 5 | 1.460 |
Why?
| | Wings, Animal | 7 | 2022 | 32 | 1.360 |
Why?
| | Mitosis | 10 | 2011 | 164 | 1.340 |
Why?
| | Wnt1 Protein | 3 | 2022 | 8 | 1.340 |
Why?
| | Tumor Suppressor Protein p53 | 6 | 2020 | 445 | 1.240 |
Why?
| | Neoplasms | 6 | 2023 | 2097 | 1.170 |
Why?
| | STAT Transcription Factors | 2 | 2017 | 13 | 1.130 |
Why?
| | Cell Cycle Proteins | 10 | 2017 | 551 | 1.130 |
Why?
| | Animals | 56 | 2024 | 31694 | 1.120 |
Why?
| | High-Throughput Screening Assays | 2 | 2023 | 123 | 1.110 |
Why?
| | Stem Cells | 3 | 2018 | 545 | 1.020 |
Why?
| | Chromosomes | 2 | 2024 | 85 | 0.950 |
Why?
| | Peptides, Cyclic | 3 | 2020 | 253 | 0.950 |
Why?
| | Loss of Heterozygosity | 2 | 2024 | 40 | 0.950 |
Why?
| | Cell Death | 5 | 2018 | 322 | 0.890 |
Why?
| | Radiation-Sensitizing Agents | 2 | 2015 | 38 | 0.870 |
Why?
| | Radiation Tolerance | 3 | 2014 | 92 | 0.870 |
Why?
| | Transcription Factor AP-1 | 1 | 2023 | 80 | 0.850 |
Why?
| | Models, Biological | 11 | 2020 | 1620 | 0.840 |
Why?
| | Larva | 8 | 2022 | 194 | 0.830 |
Why?
| | Spindle Apparatus | 6 | 2011 | 87 | 0.820 |
Why?
| | Drug Discovery | 2 | 2023 | 123 | 0.800 |
Why?
| | Gene Expression Profiling | 2 | 2022 | 1518 | 0.750 |
Why?
| | Intracellular Signaling Peptides and Proteins | 3 | 2021 | 386 | 0.750 |
Why?
| | Wound Healing | 1 | 2023 | 258 | 0.740 |
Why?
| | DNA Repair | 6 | 2020 | 184 | 0.730 |
Why?
| | Transcription Factors | 4 | 2022 | 1528 | 0.710 |
Why?
| | Embryo, Nonmammalian | 5 | 2011 | 173 | 0.700 |
Why?
| | Tumor Suppressor Proteins | 3 | 2021 | 282 | 0.690 |
Why?
| | Peptide Hydrolases | 1 | 2020 | 104 | 0.670 |
Why?
| | Salivary Glands | 1 | 2019 | 31 | 0.650 |
Why?
| | Drugs, Investigational | 1 | 2019 | 30 | 0.640 |
Why?
| | Gastrula | 3 | 2004 | 21 | 0.640 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2019 | 161 | 0.620 |
Why?
| | DNA Replication | 3 | 2010 | 202 | 0.610 |
Why?
| | Nuclear Proteins | 4 | 2009 | 591 | 0.600 |
Why?
| | Pyrophosphatases | 1 | 2017 | 22 | 0.580 |
Why?
| | E2F1 Transcription Factor | 2 | 2024 | 57 | 0.580 |
Why?
| | Disease Models, Animal | 5 | 2020 | 3531 | 0.540 |
Why?
| | Microtubule-Associated Proteins | 2 | 2009 | 174 | 0.540 |
Why?
| | Autophagy | 1 | 2018 | 233 | 0.540 |
Why?
| | Gene Expression Regulation, Developmental | 6 | 2022 | 800 | 0.530 |
Why?
| | Signal Transduction | 6 | 2023 | 4509 | 0.520 |
Why?
| | Models, Animal | 1 | 2017 | 344 | 0.520 |
Why?
| | MicroRNAs | 2 | 2014 | 600 | 0.490 |
Why?
| | Research | 1 | 2017 | 394 | 0.470 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2012 | 180 | 0.470 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2009 | 395 | 0.460 |
Why?
| | Methyl Methanesulfonate | 3 | 2010 | 5 | 0.460 |
Why?
| | Epithelial Cells | 2 | 2017 | 950 | 0.460 |
Why?
| | Mutation | 12 | 2020 | 3344 | 0.450 |
Why?
| | Heterozygote | 3 | 2024 | 251 | 0.430 |
Why?
| | Mutagens | 3 | 2010 | 17 | 0.430 |
Why?
| | DNA-Binding Proteins | 6 | 2022 | 1314 | 0.420 |
Why?
| | Genome, Insect | 1 | 2012 | 22 | 0.400 |
Why?
| | Neuropeptides | 2 | 2009 | 65 | 0.400 |
Why?
| | Chromosome Aberrations | 2 | 2024 | 135 | 0.390 |
Why?
| | Cyclin A | 2 | 2001 | 15 | 0.380 |
Why?
| | Maytansine | 1 | 2011 | 13 | 0.380 |
Why?
| | Membrane Proteins | 1 | 2017 | 1018 | 0.370 |
Why?
| | Paclitaxel | 1 | 2012 | 190 | 0.370 |
Why?
| | DNA, Satellite | 1 | 2010 | 16 | 0.370 |
Why?
| | Hydrozoa | 1 | 2010 | 1 | 0.360 |
Why?
| | Heterochromatin | 1 | 2010 | 32 | 0.360 |
Why?
| | E2F2 Transcription Factor | 1 | 2010 | 15 | 0.360 |
Why?
| | Cell Division | 3 | 2005 | 758 | 0.360 |
Why?
| | Metabolic Networks and Pathways | 1 | 2011 | 168 | 0.360 |
Why?
| | Cell Survival | 4 | 2022 | 1020 | 0.340 |
Why?
| | Biology | 1 | 2011 | 78 | 0.340 |
Why?
| | Protein Kinases | 4 | 2021 | 307 | 0.320 |
Why?
| | Educational Measurement | 1 | 2011 | 243 | 0.320 |
Why?
| | Tyrosine | 1 | 2009 | 214 | 0.320 |
Why?
| | Teaching | 1 | 2011 | 213 | 0.320 |
Why?
| | Leprosy | 2 | 2019 | 10 | 0.310 |
Why?
| | Combined Modality Therapy | 5 | 2020 | 1121 | 0.300 |
Why?
| | Cyclin E | 2 | 2007 | 21 | 0.300 |
Why?
| | Cell Movement | 2 | 2019 | 868 | 0.290 |
Why?
| | Phosphorylation | 7 | 2009 | 1569 | 0.290 |
Why?
| | Humans | 26 | 2024 | 114623 | 0.280 |
Why?
| | Students | 1 | 2011 | 501 | 0.260 |
Why?
| | Head and Neck Neoplasms | 2 | 2020 | 427 | 0.260 |
Why?
| | Telomere | 2 | 2006 | 202 | 0.260 |
Why?
| | Genes, cdc | 3 | 2006 | 10 | 0.260 |
Why?
| | CDC2 Protein Kinase | 2 | 2005 | 25 | 0.250 |
Why?
| | Gene Expression Regulation | 3 | 2009 | 2319 | 0.250 |
Why?
| | Anaphase | 2 | 2005 | 13 | 0.250 |
Why?
| | Metaphase | 2 | 2005 | 28 | 0.250 |
Why?
| | Curriculum | 1 | 2011 | 819 | 0.240 |
Why?
| | Chromosomal Instability | 1 | 2004 | 18 | 0.240 |
Why?
| | Tubulin | 1 | 2005 | 123 | 0.240 |
Why?
| | CDC2-CDC28 Kinases | 1 | 2004 | 18 | 0.230 |
Why?
| | Arthropods | 1 | 2004 | 9 | 0.230 |
Why?
| | Photoreceptor Cells, Invertebrate | 1 | 2003 | 3 | 0.230 |
Why?
| | Flow Cytometry | 3 | 2022 | 1083 | 0.220 |
Why?
| | Vertebrates | 1 | 2004 | 55 | 0.220 |
Why?
| | Telomere-Binding Proteins | 1 | 2004 | 88 | 0.220 |
Why?
| | Organogenesis | 1 | 2003 | 54 | 0.210 |
Why?
| | Cytoskeleton | 1 | 2004 | 176 | 0.210 |
Why?
| | Cell Proliferation | 5 | 2017 | 2186 | 0.210 |
Why?
| | Gene Expression | 2 | 2018 | 1421 | 0.200 |
Why?
| | Cell Line | 4 | 2023 | 2635 | 0.200 |
Why?
| | Immunoprecipitation | 3 | 2009 | 151 | 0.200 |
Why?
| | Cell Separation | 2 | 2022 | 291 | 0.200 |
Why?
| | Cell Line, Tumor | 4 | 2020 | 2710 | 0.200 |
Why?
| | Protein Biosynthesis | 2 | 2015 | 385 | 0.200 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2020 | 698 | 0.190 |
Why?
| | Alleles | 2 | 2020 | 789 | 0.190 |
Why?
| | Cell Plasticity | 1 | 2022 | 23 | 0.190 |
Why?
| | Microscopy, Confocal | 4 | 2007 | 304 | 0.190 |
Why?
| | Checkpoint Kinase 2 | 4 | 2010 | 21 | 0.190 |
Why?
| | Neurofibromin 2 | 2 | 2021 | 3 | 0.190 |
Why?
| | Blotting, Western | 4 | 2009 | 1147 | 0.180 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2020 | 40 | 0.180 |
Why?
| | Phthalazines | 1 | 2020 | 38 | 0.180 |
Why?
| | Cetuximab | 1 | 2020 | 90 | 0.180 |
Why?
| | Intracellular Space | 1 | 2020 | 68 | 0.170 |
Why?
| | Immunogenicity, Vaccine | 1 | 2020 | 25 | 0.170 |
Why?
| | RNA Interference | 3 | 2019 | 433 | 0.170 |
Why?
| | Biological Evolution | 1 | 2004 | 416 | 0.170 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2020 | 42 | 0.170 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 68 | 0.170 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2020 | 171 | 0.170 |
Why?
| | DNA | 2 | 2005 | 1352 | 0.170 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 332 | 0.170 |
Why?
| | Diacylglycerol Kinase | 1 | 2019 | 5 | 0.170 |
Why?
| | rac GTP-Binding Proteins | 1 | 2019 | 34 | 0.160 |
Why?
| | Radiobiology | 1 | 2019 | 4 | 0.160 |
Why?
| | Embryo, Mammalian | 1 | 2000 | 213 | 0.160 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2000 | 147 | 0.160 |
Why?
| | Embryonic Development | 1 | 2000 | 117 | 0.160 |
Why?
| | Cancer Vaccines | 1 | 2020 | 137 | 0.160 |
Why?
| | Adjuvants, Immunologic | 1 | 2020 | 206 | 0.160 |
Why?
| | Phenotype | 3 | 2018 | 2796 | 0.160 |
Why?
| | Molecular Imaging | 1 | 2019 | 50 | 0.160 |
Why?
| | Antigens, Neoplasm | 1 | 2020 | 221 | 0.160 |
Why?
| | Piperazines | 1 | 2020 | 309 | 0.150 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2018 | 144 | 0.150 |
Why?
| | Checkpoint Kinase 1 | 4 | 2006 | 28 | 0.150 |
Why?
| | S Phase | 2 | 2010 | 69 | 0.150 |
Why?
| | Transients and Migrants | 1 | 2017 | 22 | 0.150 |
Why?
| | Gene Silencing | 2 | 2016 | 171 | 0.150 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 384 | 0.150 |
Why?
| | MAP Kinase Signaling System | 1 | 2019 | 276 | 0.140 |
Why?
| | Protein Transport | 1 | 2018 | 395 | 0.140 |
Why?
| | Cell Lineage | 1 | 2018 | 309 | 0.140 |
Why?
| | Cell Culture Techniques | 1 | 2019 | 342 | 0.140 |
Why?
| | Radiation Injuries, Experimental | 1 | 2016 | 25 | 0.140 |
Why?
| | Neoplastic Stem Cells | 1 | 2020 | 329 | 0.130 |
Why?
| | Cell Polarity | 1 | 2017 | 131 | 0.130 |
Why?
| | Immunotherapy | 1 | 2020 | 474 | 0.130 |
Why?
| | Cells, Cultured | 2 | 2019 | 3881 | 0.130 |
Why?
| | Cost of Illness | 1 | 2017 | 254 | 0.130 |
Why?
| | Reproducibility of Results | 1 | 2023 | 2762 | 0.130 |
Why?
| | Receptors, TIE | 1 | 2015 | 1 | 0.130 |
Why?
| | Genetic Testing | 1 | 2017 | 379 | 0.120 |
Why?
| | Time Factors | 5 | 2005 | 6112 | 0.120 |
Why?
| | Fluorescent Antibody Technique | 2 | 2005 | 397 | 0.120 |
Why?
| | HeLa Cells | 1 | 2015 | 562 | 0.110 |
Why?
| | Morphogenesis | 2 | 2005 | 159 | 0.110 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2015 | 270 | 0.110 |
Why?
| | Colorectal Neoplasms | 1 | 2020 | 615 | 0.110 |
Why?
| | Cyclin-Dependent Kinases | 2 | 2004 | 111 | 0.110 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2020 | 127 | 0.100 |
Why?
| | X-Rays | 2 | 2004 | 30 | 0.100 |
Why?
| | Brain | 1 | 2004 | 2371 | 0.100 |
Why?
| | Glioma | 1 | 2015 | 294 | 0.100 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2011 | 23 | 0.100 |
Why?
| | Tuberous Sclerosis | 1 | 2011 | 36 | 0.090 |
Why?
| | Mental Disorders | 1 | 2019 | 892 | 0.090 |
Why?
| | Mice | 5 | 2020 | 14860 | 0.090 |
Why?
| | Embryology | 1 | 2011 | 1 | 0.090 |
Why?
| | HCT116 Cells | 1 | 2011 | 70 | 0.090 |
Why?
| | Mitotic Index | 1 | 2010 | 26 | 0.090 |
Why?
| | Drug Design | 1 | 2011 | 148 | 0.090 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 740 | 0.090 |
Why?
| | Green Fluorescent Proteins | 2 | 2008 | 371 | 0.080 |
Why?
| | Goals | 1 | 2011 | 147 | 0.080 |
Why?
| | Peer Group | 1 | 2011 | 201 | 0.080 |
Why?
| | Amino Acid Sequence | 2 | 2003 | 1982 | 0.080 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 134 | 0.080 |
Why?
| | Biological Products | 1 | 2012 | 166 | 0.080 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2009 | 345 | 0.080 |
Why?
| | Biomarkers | 1 | 2018 | 3408 | 0.080 |
Why?
| | Molecular Sequence Data | 2 | 2003 | 2785 | 0.080 |
Why?
| | Quality of Life | 1 | 2019 | 2353 | 0.080 |
Why?
| | Gene Deletion | 2 | 2015 | 356 | 0.080 |
Why?
| | Kinetochores | 1 | 2008 | 44 | 0.080 |
Why?
| | China | 2 | 2019 | 161 | 0.070 |
Why?
| | Survival Analysis | 1 | 2011 | 1211 | 0.070 |
Why?
| | Brain Neoplasms | 1 | 2015 | 979 | 0.070 |
Why?
| | 3' Untranslated Regions | 1 | 2008 | 129 | 0.070 |
Why?
| | Gene Dosage | 1 | 2008 | 129 | 0.070 |
Why?
| | Xenopus | 2 | 2005 | 97 | 0.070 |
Why?
| | E2F Transcription Factors | 1 | 2007 | 55 | 0.070 |
Why?
| | Learning | 1 | 2011 | 350 | 0.070 |
Why?
| | Cytokinesis | 1 | 2007 | 46 | 0.070 |
Why?
| | Gastrin-Releasing Peptide | 1 | 2005 | 6 | 0.060 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2006 | 29 | 0.060 |
Why?
| | Microscopy, Fluorescence | 2 | 2005 | 396 | 0.060 |
Why?
| | Chromatography, Affinity | 1 | 2005 | 80 | 0.060 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2005 | 100 | 0.060 |
Why?
| | Centrosome | 1 | 2005 | 59 | 0.060 |
Why?
| | RNA, Messenger | 1 | 2012 | 2552 | 0.060 |
Why?
| | Transgenes | 1 | 2005 | 170 | 0.060 |
Why?
| | Acid Anhydride Hydrolases | 1 | 2004 | 5 | 0.060 |
Why?
| | Female | 7 | 2020 | 59466 | 0.060 |
Why?
| | DNA Repair Enzymes | 1 | 2004 | 22 | 0.060 |
Why?
| | Models, Genetic | 2 | 2006 | 562 | 0.060 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2004 | 63 | 0.060 |
Why?
| | Sequence Analysis, DNA | 2 | 2006 | 723 | 0.060 |
Why?
| | Enzyme Activation | 1 | 2006 | 785 | 0.060 |
Why?
| | Cleavage Stage, Ovum | 1 | 2004 | 7 | 0.060 |
Why?
| | Egg Proteins | 1 | 2004 | 19 | 0.060 |
Why?
| | Retinoblastoma Protein | 1 | 2004 | 52 | 0.060 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 2004 | 32 | 0.060 |
Why?
| | Embryonic and Fetal Development | 1 | 2004 | 94 | 0.060 |
Why?
| | Invertebrates | 1 | 2004 | 21 | 0.060 |
Why?
| | Bromodeoxyuridine | 1 | 2004 | 72 | 0.060 |
Why?
| | Gene Targeting | 1 | 2004 | 75 | 0.060 |
Why?
| | Fertilization | 1 | 2004 | 41 | 0.060 |
Why?
| | Macromolecular Substances | 1 | 2004 | 200 | 0.060 |
Why?
| | X Chromosome | 1 | 2003 | 47 | 0.050 |
Why?
| | Models, Anatomic | 1 | 2004 | 87 | 0.050 |
Why?
| | Substrate Specificity | 1 | 2004 | 352 | 0.050 |
Why?
| | Crosses, Genetic | 1 | 2003 | 139 | 0.050 |
Why?
| | Body Patterning | 1 | 2004 | 126 | 0.050 |
Why?
| | Sequence Alignment | 1 | 2003 | 323 | 0.050 |
Why?
| | DNA Transposable Elements | 1 | 2003 | 101 | 0.050 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2003 | 353 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 923 | 0.050 |
Why?
| | Telomerase | 1 | 2004 | 206 | 0.050 |
Why?
| | Fertility | 1 | 2003 | 130 | 0.050 |
Why?
| | Recombination, Genetic | 1 | 2003 | 176 | 0.050 |
Why?
| | Mass Spectrometry | 1 | 2005 | 633 | 0.050 |
Why?
| | Mammals | 1 | 2004 | 244 | 0.050 |
Why?
| | Structure-Activity Relationship | 1 | 2003 | 502 | 0.050 |
Why?
| | Saccharomyces cerevisiae | 1 | 2005 | 476 | 0.050 |
Why?
| | Protein Processing, Post-Translational | 1 | 2004 | 399 | 0.050 |
Why?
| | Male | 5 | 2019 | 55554 | 0.050 |
Why?
| | Temperature | 1 | 2004 | 565 | 0.050 |
Why?
| | Amino Acid Motifs | 1 | 2001 | 197 | 0.050 |
Why?
| | DNA End-Joining Repair | 1 | 2020 | 15 | 0.050 |
Why?
| | Proof of Concept Study | 1 | 2020 | 45 | 0.050 |
Why?
| | Ubiquitination | 1 | 2021 | 86 | 0.050 |
Why?
| | Cell Nucleus | 1 | 2003 | 554 | 0.040 |
Why?
| | Proteolysis | 1 | 2021 | 142 | 0.040 |
Why?
| | Theranostic Nanomedicine | 1 | 2020 | 8 | 0.040 |
Why?
| | Blastoderm | 1 | 2000 | 1 | 0.040 |
Why?
| | Clone Cells | 1 | 2020 | 247 | 0.040 |
Why?
| | DNA, Neoplasm | 1 | 2020 | 157 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2011 | 1879 | 0.040 |
Why?
| | Peptide Chain Elongation, Translational | 1 | 2020 | 18 | 0.040 |
Why?
| | Drug Synergism | 1 | 2020 | 316 | 0.040 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2000 | 64 | 0.040 |
Why?
| | Cell Size | 1 | 2000 | 80 | 0.040 |
Why?
| | Heat-Shock Response | 1 | 2000 | 46 | 0.040 |
Why?
| | Cyclins | 1 | 2000 | 78 | 0.040 |
Why?
| | Phylogeny | 1 | 2003 | 789 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2004 | 1629 | 0.040 |
Why?
| | Staining and Labeling | 1 | 2000 | 134 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2020 | 244 | 0.040 |
Why?
| | Base Sequence | 1 | 2003 | 2114 | 0.040 |
Why?
| | Cisplatin | 1 | 2020 | 262 | 0.040 |
Why?
| | Cell Count | 1 | 2000 | 303 | 0.040 |
Why?
| | Mice, Nude | 1 | 2020 | 630 | 0.040 |
Why?
| | Histones | 1 | 2004 | 535 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2003 | 1842 | 0.040 |
Why?
| | Antigen Presentation | 1 | 2020 | 188 | 0.040 |
Why?
| | Nanotechnology | 1 | 2020 | 113 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2020 | 188 | 0.040 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 193 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2019 | 4405 | 0.040 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 152 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2004 | 2565 | 0.040 |
Why?
| | Microscopy | 1 | 2019 | 125 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2020 | 554 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2020 | 435 | 0.030 |
Why?
| | Nanoparticles | 1 | 2020 | 313 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2000 | 436 | 0.030 |
Why?
| | Receptor, TIE-2 | 1 | 2015 | 12 | 0.030 |
Why?
| | Protein Binding | 1 | 2021 | 1889 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1141 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1313 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 858 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2020 | 1736 | 0.030 |
Why?
| | Middle Aged | 2 | 2019 | 26719 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 4620 | 0.020 |
Why?
| | Adult | 2 | 2019 | 30528 | 0.020 |
Why?
| | G2 Phase | 1 | 2005 | 31 | 0.020 |
Why?
| | Hydroxyurea | 1 | 2005 | 30 | 0.020 |
Why?
| | Xenopus Proteins | 1 | 2005 | 55 | 0.020 |
Why?
| | DNA, Complementary | 1 | 2005 | 256 | 0.010 |
Why?
| | RNA-Binding Proteins | 1 | 2006 | 344 | 0.010 |
Why?
| | Young Adult | 1 | 2017 | 10455 | 0.010 |
Why?
| | Aged | 1 | 2019 | 19061 | 0.010 |
Why?
| | RNA | 1 | 2005 | 809 | 0.010 |
Why?
|
|
Su's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|